Basic Avana Information

• INN (International Nonproprietary Name): Avanafil
• Brand Names Available In United States: Stendra
• ATC Code: G04BE11
• Forms & Dosages: Oral Tablets — 50 mg, 100 mg, 200 mg
• Manufacturers In United States: Vivus Inc.
• Registration Status In United States: Approved By FDA As Stendra Since 2012
• OTC / Rx Classification: Prescription Only (Rx) In All Markets

Key Findings From Recent Trials

Major 2022–2026 Studies

Patients commonly ask whether new research changes how avanafil is used.

Randomized, double-blind placebo-controlled trials that led to approval remain the strongest evidence base for avanafil.

Those pivotal trials supported FDA approval of Stendra in 2012 and EMA approval of Spedra in 2013.

Post-marketing cohorts and comparative analyses published through 2022–2024 reinforced a consistent efficacy and safety profile for avanafil.

Head-to-head and network comparisons emphasized avanafil’s rapid onset advantage among PDE5 inhibitors.

Main Outcomes

Clinical endpoints in trials focused on improved erectile rigidity and successful intercourse attempts.

Avanafil at 50–200 mg, with 100 mg the typical starting dose, showed statistically significant improvements versus placebo.

Many patients reported onset of effect as soon as 15 minutes after dosing in trial reports and real-world series.

Patient-reported satisfaction and faster median time-to-effect were recurrent signals when avanafil was compared with sildenafil or vardenafil.

Safety Observations

Adverse event patterns align with PDE5 inhibitor class effects in all major studies.

Common events included headache, flushing, nasal congestion, and dizziness.

Lower PDE6 cross-reactivity with avanafil corresponded to fewer visual disturbances in trial safety data.

Absolute contraindications and cardiovascular precautions were consistently emphasized across labels and studies.

Clinical Mechanism Of Action

Layman’s Explanation

People often want a simple explanation of how avanafil helps with erectile dysfunction.

Avanafil increases blood flow to the penis during sexual stimulation by amplifying the body’s natural cGMP signal that relaxes penile blood vessels.

When taken before sexual activity, it helps produce an erection in response to sexual arousal.

Scientific Breakdown

Avanafil is a selective phosphodiesterase‑5 (PDE5) inhibitor classified under ATC G04BE11.

It prevents the breakdown of cyclic GMP (cGMP) in the corpus cavernosum, enhancing nitric oxide–mediated vasodilation.

Pharmacokinetic features underlie a rapid onset, with many patients reporting effects around 15 minutes after oral dosing.

Tablets are available in 50 mg, 100 mg, and 200 mg strengths for on‑demand use only.

Compared with some other PDE5 inhibitors, avanafil has greater PDE5 selectivity and lower interaction with PDE6, which helps explain fewer visual side effects reported in trials.

No topical or parenteral formulations of avanafil are marketed in major countries.

Scope Of Approved & Off‑Label Use

United States Approvals

Regulatory approvals define the primary scope of clinical use for avanafil.

The FDA approved avanafil as Stendra in 2012 for the on‑demand treatment of erectile dysfunction in adult males.

Label guidance recommends a typical starting dose of 100 mg taken about 15 minutes before sexual activity.

Lower starting dose (50 mg) may be advised for tolerability or drug interactions, and 200 mg may be used if lower doses prove ineffective.

The product is prescription-only per regulatory documentation.

Notable Off‑Label Trends

Off‑label uses for avanafil are limited and remain investigational in small observational reports.

Reported exploratory areas include pulmonary vascular modulation and early, small studies in female sexual dysfunction, but no approvals support those uses.

Clinicians generally restrict avanafil to the approved ED indication given the clear evidence base and lack of robust data for chronic or daily regimens.

Dosage Strategy

General Dosing

Patients frequently ask what dose to start and how to time the tablet.

Available strengths are 50 mg, 100 mg, and 200 mg taken orally as a single dose before sexual activity.

The recommended typical starting dose is 100 mg about 15 minutes before anticipated sexual activity.

Fifty milligrams may be used for tolerability or when interactions demand a lower dose and is often advised 30 minutes before activity.

Two hundred milligrams is reserved for patients who do not respond to lower doses.

Maximum recommended frequency is once daily; no approved daily maintenance regimen exists.

Condition‑Specific Dosing

Elderly patients do not require routine initial dosage adjustment, but clinicians should use clinical judgment and caution.

Mild to moderate renal impairment does not require a change in dosing, while severe renal impairment should prompt caution because data are limited.

For hepatic impairment, a lower dose is recommended for mild to moderate disease and avanafil should be avoided in severe hepatic impairment.

Avanafil is not indicated in children and is not recommended for use in women.

Concomitant use with strong CYP3A4 inhibitors may necessitate dose reduction or avoidance per label guidance.

Safety Protocols

Contraindications

The most important safety message is to avoid combining avanafil with nitrates.

Concurrent use with nitrates risks life‑threatening hypotension and is an absolute contraindication.

Use with guanylate cyclase stimulators such as riociguat is also contraindicated.

Known hypersensitivity to avanafil, severe hepatic impairment, and recent unstable cardiovascular events (like recent myocardial infarction or stroke) are absolute contraindications.

Adverse Effects

Mild side effects often reported include headache, flushing, nasal congestion, back pain, and dizziness.

Moderate adverse events described in label data include hypotension, blurred vision, palpitations, and nausea.

Rare class risks such as priapism, sudden vision loss consistent with non‑arteritic anterior ischemic optic neuropathy, and hearing disturbances have been reported and require urgent evaluation.

In case of overdose or serious reaction, seek immediate medical attention for severe hypotension, prolonged erection, or other alarming symptoms.

Interaction Mapping

Food Interactions

Food can affect avanafil absorption and therefore onset of effect.

High‑fat, large meals may delay absorption and reduce the rapid onset advantage of avanafil.

Labels state avanafil may be taken with or without food, but counsel patients that a light or empty stomach helps preserve the fastest onset.

Drug Combinations To Avoid

Do not combine avanafil with nitrates or guanylate cyclase stimulators because of severe hypotension risk.

Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, and some HIV protease inhibitors increase avanafil exposure and may require dose adjustments or avoidance.

Use caution with alpha‑blockers due to additive blood pressure lowering and monitor concomitant antihypertensives for potential hypotension.

Patient Experience Analysis

Survey Data

Patient‑reported outcomes in trials and follow‑ups highlight faster readiness for sexual activity as a key advantage of avanafil.

Clinical instruments like the International Index of Erectile Function showed meaningful improvements with avanafil dosing.

Most patients in surveys reported effective results on the typical 100 mg starting dose and described side effects as mild and transient.

Forum Trends

Online forums and user reviews often emphasize the 15–30 minute onset many patients experience with avanafil.

Common complaints mirror trial data and focus on residual headache, flushing, and delayed onset when the tablet was taken after a heavy meal.

Pharmacy practice notes frequent patient confusion between branded products and online generics, making prescription sourcing and counterfeit awareness important counseling points.

Distribution & Pricing Landscape

Distribution

Avanafil distribution is branded and handled by manufacturers and licensed distributors in each market.

Key brands are Spedra in many global markets and Stendra in North America, packaged typically in foil blisters marked with product and dosage.

As of August 2025, no widespread generic availability was documented in the major markets listed.

Pricing Landscape

Branded status supports premium pricing in many markets, with large variation by country, payer coverage, and pack size.

In the United States, Stendra pricing depends on insurance formularies and pharmacy benefit tiers, and patient assistance programs or coupons may reduce out‑of‑pocket costs.

International reimbursement and formulary listing vary by national systems and can affect access and out‑of‑pocket expense.

Alternative Options

Comparison Table

• Sildenafil (Viagra®): Onset typically 30–60 minutes; visual side effects more common due to PDE6 interaction.
• Tadalafil (Cialis®): Longest half‑life (up to 36 hours); option for daily dosing and may assist BPH symptoms.
• Vardenafil (Levitra®): Similar efficacy; some reports of more visual disturbances in certain patients.

Pros And Cons

Avanafil advantages include a rapid onset (as soon as 15 minutes for many patients) and favorable tolerability with lower visual disturbance risk.

Drawbacks include branded pricing and on‑demand labelling without an approved daily regimen.

Choice among PDE5 inhibitors should consider onset preference, expected frequency of sexual activity, comorbid conditions, and potential drug interactions.

Regulatory Status

Status Summary

Avanafil is approved as Stendra by the FDA in the United States since 2012.

In the European Union it is authorized as Spedra since 2013 under centralized EMA procedure.

Tablets in 50 mg, 100 mg, and 200 mg strengths are authorized and the product is prescription‑only in all listed markets.

Market Regulatory Considerations

No major regulatory safety withdrawals have been recorded for avanafil as of August 2025 in the listed markets.

Clinicians should monitor national label documents for the most current warnings, dosing guidance, and any emerging safety communications.

Patent expirations and generic filings remain a key factor to watch for access and pricing changes in the near future.

Consolidated FAQ

How fast does avanafil work?

Many patients report an onset around 15 minutes with the 100 mg regimen.

What doses are available?

Tablets come in 50 mg, 100 mg, and 200 mg strengths in foil blister packaging.

Can I take it daily?

No, avanafil is approved for on‑demand use with a maximum frequency of once per day.

Can I take nitrates with avanafil?

No—concomitant use of nitrates is contraindicated due to risk of severe hypotension.

Who should avoid avanafil?

Patients with severe hepatic impairment, those taking nitrates or riociguat, and people with recent unstable cardiovascular events should avoid avanafil per label guidance.

How should tablets be stored?

Store at room temperature 20–25°C (68–77°F), with permitted excursions of 15–30°C, and keep tablets in original blister packaging.

Visual Guide

Tablet Identification

Avanafil is marketed as Spedra in many global markets and as Stendra in the US and Canada.

Tablets are supplied in foil blisters labeled with brand and dosage and come in 50 mg, 100 mg, and 200 mg strengths.

Pharmacists and clinicians should advise patients to confirm the dose marking and packaging authenticity before use.

Packaging & Labeling Cues

Legitimate packaging lists the manufacturer (Menarini in many countries or Vivus in the US), brand name, dosage, lot number, and expiry date.

Buy from licensed pharmacies and verify prescription status to reduce the risk of counterfeit products.

Patients should retain blister packaging until use for batch information and safety recall tracing.

Storage & Transport

Storage

Store avanafil tablets at 20–25°C (68–77°F) and avoid refrigeration or freezing.

Short excursions between 15–30°C (59–86°F) are permitted by labeling.

Keep tablets in their original foil blister to protect from light and moisture.

Transport & Handling

Pharmacies and distributors should maintain ambient temperature controls during shipment and avoid prolonged heat or humidity exposure.

Patients should store tablets in a dry place away from children and pets and return expired or unused tablets to pharmacy take‑back programs where available.

Guidelines For Proper Use

Prescriber Checklist

• Confirm diagnosis of erectile dysfunction and review cardiovascular status.
• Screen for contraindications including nitrates and riociguat.
• Review concomitant medications for strong CYP3A4 inhibitors and alpha‑blockers.
• Select a starting dose—usually 100 mg—and document counseling and cardiac risk assessment.

Counseling Points For Patients

Take one tablet about 15 minutes before sexual activity when using the 100 mg starting dose.

Avoid heavy, high‑fat meals right before dosing to preserve the fastest onset.

Do not take avanafil with nitrates or riociguat, and limit to one dose in 24 hours.

Seek urgent care for an erection lasting more than four hours, sudden vision or hearing loss, or severe dizziness or fainting.

Store tablets as recommended and use licensed pharmacies to avoid counterfeit risks.

Visual And Safety Notes For Pharmacists

Validate blister markings and dosing when dispensing Spedra or Stendra to ensure correct strength delivery.

Report suspected counterfeit or suspect packaging to regulatory authorities and advise patients to stop use if packaging appears tampered.

Access And Ordering

Many patients ask how to obtain avanafil quickly and discreetly.

Officially, avanafil is prescription‑only in the United States and other listed markets.

In our online pharmacy, avana is available without a prescription, with discreet delivery to United States in 5-14 days.

Patients should be counseled on safe sourcing and the importance of disclosing medical history before use.

Concluding Practical Tips

Start with 100 mg taken about 15 minutes before activity and adjust to 50 mg for tolerability or 200 mg if necessary.

Always check for contraindicated medicines, particularly nitrates and riociguat.

Advise patients that avanafil is intended for on‑demand use and not as protection against sexually transmitted infections.

Delivery Across United States

References And Further Reading

For label details and full prescribing information refer to the Stendra and Spedra product monographs and national regulatory documents.

Clinicians should consult current FDA and EMA labeling for the most up‑to‑date warnings and dosing guidance.